Barole Rabeprazole Sodium Capsules

BAROLE (Enteric coated Rabeprazole Sodium Capsules 10mg/20mg)

Description, Composition, Inactive ingredients, Clinical pharmacology, Pharmacokinetics, Special populations, Indication and usage, Contraindications, Precautions, Adverse reactions, Drug interactions, Overdosage and treatment, Dosage and administration, Storage instructions, Shelf life, Presentation, NAFDAC Registration number, Owner and Manufacturer of Barole Capsule Medicine for Ulcer.

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.

 

DESCRIPTION

BAROLE, brand of Enteric coated Rabeprazole Sodium Capsules, contains Rabeprazole, which is a substituted benzimidazole that inhibits gastric acid secretion.
Rabeprazole sodium is known chemically as:

2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]sulfinyl]-1H-benzimidazole sodium salt. It has an empirical formula of C18H20N3NaO3S and a molecular weight of 381.43.

 

COMPOSITION

BAROLE 10

Each capsule contains:

Rabeprazole Sodium 10mg

(As enteric coated pellets)

 

BAROLE 20

Each capsule contains:

Rabeprazole Sodium 20mg

(As enteric coated pellets)

 

INACTIVE INGREDIENTS

Hypromellose, Methacrylic Acid Copolymer, Macrogol, Purified Talc, Light Magnesium Carbonate, Sodium Hydroxide.

 

CLINICAL PHARMACOLOGY

Rabeprazole belongs to a class of antiaecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-recptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+, K+ ATPase at the secretory surface of the gastric parietal cell. Because this enzyme if regarded as the acid (proton) pump within the parietal cell, Rabeprazole has been characterized as a gastric proton- pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, Rabeprazole is protonated, accumulates, and is transformed to an active sulfonamide.

 

PHARMACOKINETICS

After oral administration of 20 mg Rabeprazole, peak plasma concentrations (Cmax) of Rabeprazole occur over a range of 2.0 to 5.0 hours (Tmax). There is no appreciable accumulation when doses of 10 mg to 40 mg are administered every 24 hours; the pharmacokinetics of Rabeprazole is not altered by multiple dosing. The plasma half-life ranges from 1 to 2 hours.

Following oral administration of 20 mg Rabeprazole, it is absorbed and can be detected in plasma by 1 hour. Absolute bioavailability for a 20 mg oral capsule of Rabeprazole is approximately 52%. Rabeprazole is 96.3% bound to human plasma proteins.

Rabeprazole is extensively metabolized. The thioether and sulphone are the primary metabolites measured in human plasma. These metabolites were not observed to have significant antisecretory activity. In vitro studies have demonstrated that Rabeprazole is primarily metabolized in the liver by cytochromes P450 3A (sulphone metabolite) and 2C19 (desmethyl Rabeprazole): 90% of the drug is eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites.

The anti-secretory effect begins within one hour after oral administration of 20mg Rabeprazole. The median inhibitory effect of Rabeprazole on 24 hour gastric acidity is 88% of maximal after the first dose. Rabeprazole 20 mg inhibits basal and peptone meal-stimulated acid secretion versus placebo by 86% and 95%, respectively and increases the percent of a 24-hour period that the gastric pH>3 from 10% to 65%. This relatively prolonged pharmacodynamic action compared to the short pharmacokinetic half-life (1-2 hours) reflects the sustained inactivation of the H+, K+ATPase.

 

SPECIAL POPULATIONS

Geriatric: Reported data from clinical studies in healthy elderly subjects indicates that AUC values are approximately doubled and Cmax increased by 60% compared to values in a parallel younger control group. There was no evidence of drug accumulation after once daily dosing.

Pediatric: The pharmacokinetics of Rabeprazole in pediatrics has not been studied.

Gender and race: In analyais of body mass and weight, Rabeprazole pharmacoklnetics showed no clinically significant diffeiences between male and female volunteers.

Renal disease: No clinically significant difference was observed in the pharmacokinetics of Rabeprazole between healthy volunteers and patients requiring maintenance haemodialysis.

Hepatlc disease: Reported data from single dose clinical study indicates that AUC & elimination half lives are doubled in patients with mild to moderate liver cirrhosis as compared to healthy volunteers. No information exists on Rabeprazole disposition in patients with severe hepatic impairment.

 

INDICATION AND USAGE

Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD): Rabeprazole is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD).

Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD): Rabeprazole is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance).

Healing of Duodenal Ulcers: Rabeprazole is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. It is highly effective in the presence of H.Pylori.

Treatment of Pathological hypersecretory Conditions, Including Zollinger-Ellison Syndrome: Rabeprazole is indicated for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome.

 

CONTRAINDICATIONS

Rabeprazole is contraindicated in patients with known hypersensitivity to Rabeprazole, substituted benzimidazole or to any component of the formulation.

 

PRECAUTIONS

Symptomatic response to therapy with Rabeprazole does not preclude the presence of gastric malignancy.

 

Pregnancy & Lactation

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Since many drugs are excreted in milk, caution should be exercised when Rabeprazole is administered to a nursing mother.

 

Pediatric Use

The safety and effectiveness of Rabeprazole in pediatric patients have not been established.

 

Geriatric Use

No overall differences in safety or effectiveness were observed between geriatric subjects and younger subjects.

 

Effects on ability to drive and use machine

It should be taken into account that occasionally dizziness may occur.

 

ADVERSE REACTIONS

Adverse effects with Rabeprazole are mild to moderate in intensity and include malaise, diarrhea, nausea, skin eruptions, headache and dizziness.

Abnormal laboratory findings (increased hepatic enzymes, LDH, blood urea nitrogen) observed with Rabeprazole were similar in incidence and severity with comparator agents and reversible with cessation of therapy. Inform your doctor in case of any adverse reactions related to drug use.

 

DRUG INTERACTIONS

Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system. Rabeprazole does not have clinically significant interactions with other drugs metabolized by the CYP45O system, such as wartfarin, theophylline, diazepam and phenytoin.

Rabeprazole produces sustained inhibition of gastric acid secretion. An interaction with compounds which are dependent on gastric pH for absorption like ketoconazole may occur due to the magnitude of acid suppression observed with Rabeprazole. Therefore, patients may need to be monitored when such drugs are taken concomitantly with Rabeprazole. Co-administration of Rabeprazole and antacids produced no clinically relevant changes in plasma Rabeprazole concentrations.

 

OVERDOSAGE AND TREATMENT

There has been no experience with large overdoses with Rabeprazole.
Patients with Zollinger-Ellison syndrome have been treated with up to 120mg Rabeprazole QD. No specific antidote for Rabeprazole is known. Rebeprazole is extensively protein bound and its not readily dialyzable. In the event of overdose, treatment should be symptomatic and supportive.

 


DOSAGE AND ADMINISTRATION

BAROLE should be administered before meals.

Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD): The recommended adult oral dose is 20 mg Rabeprazole to be taken daily for four to eights weeks.

Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD Maintenance): The recommended adult oral dose is 20 mg Rabeprazole to be taken daily.

Healing of Duodenal Ulcers: The recommended adult oral dose is 20mg Rabeprazole to be taken daily after the morning meal for a period up to four weeks. Most patients with duodenal ulcer heal within four weeks.

Treatment of Pathological hypersecretory Conditions, including Zollinger-Ellison Syndrome:

The dosage of Rabeprazole in patients with hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Doses up to 100mg QD and 60mg BID have been administered.

No dosage adjustment is necessary in elderly patients, in patients with renal disease or in patients with mild to moderate hepatic impairment. Administration of Rabeprazole to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Due to the lack of clinical data on Rabeprazole in patients with severe hepatic impairment, caution should be exercised in those patients.

Barole Capsules should be swallowed whole. The Capsules should not be chewed, crushed or split.

 

STORAGE INSTRUCTIONS

Store below 25°C. Protect from light and moisture.

 

SHELF LIFE

24 Months

 

PRESENTATION

BAROLE Capsules are available in strengths of 10mg & 20mg. l0 capsules in each strip.

• 100 capsules (10 x 10’s) in a box

• 30 capsules (3 x 10’s) in a box

 

NOTE:

• Read the instructions thoroughly before use.

• Use upon doctor’s prescription only.

• Please do not use the drug after the expiry date.

• Please do not use the drug if there are any significant changes in appearance of the capsules.

• Keep Out of reach of children.

 

NAFDAC Reg. No.:

 

Manufactured for

MEGA LIFE SCIENCES (AUSTRALIA) PTY LTD

(ACN 076 713 392), Victoria 3175 Australia.

 

Manufactured by

INVENTIA HEALTHCARE PVT. LTD.

F1-F1/1, Additional Ambernath, M.I.D.C,

Ambemath (East)- 421 506, Dist. Thane, India.

Advertisements